264 related articles for article (PubMed ID: 37535601)
1. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.
Cheraghi-Shavi T; Jalal R; Minuchehr Z
PLoS One; 2023; 18(8):e0289535. PubMed ID: 37535601
[TBL] [Abstract][Full Text] [Related]
2. Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53.
Wang WL; Batzorig U; Hung CS; Wei PL; Huang CY; Chang YJ
Biomed Res Int; 2022; 2022():1322788. PubMed ID: 35178443
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
[TBL] [Abstract][Full Text] [Related]
4. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
5. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
6. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
[TBL] [Abstract][Full Text] [Related]
8. Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer.
Xu Y; Zhu M
Clin Transl Oncol; 2020 Jul; 22(7):1105-1116. PubMed ID: 31728833
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel miRNAs, Targeting Genes, Signaling Pathway, and the Small Molecule for Overcoming Oxaliplatin Resistance of Metastatic Colorectal Cancer.
Misbah M; Kumar M; Lee KH; Shen SC
Biomed Res Int; 2022; 2022():3825760. PubMed ID: 36193307
[TBL] [Abstract][Full Text] [Related]
10. In silico analysis to identify miR-1271-5p/PLCB4 (phospholipase C Beta 4) axis mediated oxaliplatin resistance in metastatic colorectal cancer.
Lee CC; Lee AW; Wei PL; Liu YS; Chang YJ; Huang CY
Sci Rep; 2023 Mar; 13(1):4366. PubMed ID: 36927770
[TBL] [Abstract][Full Text] [Related]
11. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
[TBL] [Abstract][Full Text] [Related]
12. The identification of a common different gene expression signature in patients with colorectal cancer.
Zhao ZW; Fan XX; Yang LL; Song JJ; Fang SJ; Tu JF; Chen MJ; Zheng LY; Wu FZ; Zhang DK; Ying XH; Ji JS
Math Biosci Eng; 2019 Apr; 16(4):2942-2958. PubMed ID: 31137244
[TBL] [Abstract][Full Text] [Related]
13. Identifying the key genes and microRNAs in colorectal cancer liver metastasis by bioinformatics analysis and in vitro experiments.
Zhang T; Guo J; Gu J; Wang Z; Wang G; Li H; Wang J
Oncol Rep; 2019 Jan; 41(1):279-291. PubMed ID: 30542696
[TBL] [Abstract][Full Text] [Related]
14. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.
Hong B; Lu R; Lou W; Bao Y; Qiao L; Hu Y; Liu K; Chen J; Bao D; Ye M; Fang Z; Gong C; Zhang X
Exp Cell Res; 2021 Oct; 407(2):112827. PubMed ID: 34508743
[TBL] [Abstract][Full Text] [Related]
15. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
Bommer UA; Vine KL; Puri P; Engel M; Belfiore L; Fildes K; Batterham M; Lochhead A; Aghmesheh M
Cell Commun Signal; 2017 Feb; 15(1):9. PubMed ID: 28143584
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
17. A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer.
Deng X; Kong F; Li S; Jiang H; Dong L; Xu X; Zhang X; Yuan H; Xu Y; Chu Y; Peng H; Guan M
Cell Death Dis; 2021 May; 12(5):485. PubMed ID: 33986248
[TBL] [Abstract][Full Text] [Related]
18. Identification of potential therapeutic targets associated with diagnosis and prognosis of colorectal cancer patients based on integrated bioinformatics analysis.
Sharma A; Yadav D; Rao P; Sinha S; Goswami D; Rawal RM; Shrivastava N
Comput Biol Med; 2022 Jul; 146():105688. PubMed ID: 35680454
[TBL] [Abstract][Full Text] [Related]
19. Gamma-Aminobutyric Acid Type A Receptor Subunit Pi is a potential chemoresistance regulator in colorectal cancer.
Wang T; Zhen Q; Wu T; Jin L; Yao S; Feng Y; Chen J; Chen C; Huang Z
Mol Biol Rep; 2023 Apr; 50(4):3167-3177. PubMed ID: 36696022
[TBL] [Abstract][Full Text] [Related]
20. Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells.
Li X; Ma Y; Wu J; Ni M; Chen A; Zhou Y; Dai W; Chen Z; Jiang R; Ling Y; Yao Q; Chen W
Drug Resist Updat; 2023 Mar; 67():100930. PubMed ID: 36736043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
